A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/6/2019
Start Date:October 5, 2010
End Date:July 31, 2019

Use our guide to learn which trials are right for you!

A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

This is a first-in-man trial, in which BYL719 will be administered to adult patients with
advanced solid tumors, whose tumors have an alteration of the PIK3CA gene and whose disease
has progressed despite standard therapy or for whom no standard therapy exists. A combination
of BYL719 with fulvestrant will also be investigated in post-menopausal patients with locally
advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene. The
single agent MTD dose expansion cohort and the fulvestrant combination MTD dose expansion
cohort will also include ER+/HER2- breast cancer patients whose tumors have the wild type
PIK3CA gene


Inclusion Criteria:

- Patients with histologically-confirmed, advanced unresectable solid tumors who have
progressed within three months before screening/baseline visit Only patients who have
confirmed PIK3CA status (wild type, mutation or amplification) will be allowed for
screening (patients participating in the combination arm must be eligible for
treatment with fulvestrant)

- Availability of a representative formalin fixed paraffin embedded tumor tissue sample

- At least one measurable or non-measurable lesion

- Age ≥ 18 years

- World Health Organization (WHO) Performance Status ≤ 2

- Good organ (hepatic, kidney, BM) function at screening/baseline visit

Exclusion Criteria:

- Brain metastasis unless treated and free of signs/symptoms attributable to brain
metastasis in the absence of corticosteroid therapy (anti-epileptic therapy is
allowed).

- Prior treatment with PI3K, AKT or mTOR inhibitor and failure to benefit

- Patient with peripheral neuropathy NCI-CTC Grade ≥ 3

- Patient with diarrhea NCI-CTC Grade ≥ 2

- Patient with acute or chronic pancreatitis

- Impaired cardiac function or clinically significant cardiac disease incl. unstable
angina pectoris ≤ 3 months prior to starting study drug and Acute Myocardial
Infarction (AMI) ≤ 3 months prior to starting study drug.

- Patients with clinically manifest diabetes mellitus, history of gestational diabetes
mellitus or documented steroid-induced diabetes mellitus

- Women who are pregnant or breast feeding or adults of reproductive potential not
employing an effective method of birth control

Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
6
sites
?
mi
from
Essen,
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Nashville, Tennessee 37232
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
San Francisco, California 94115
?
mi
from
San Francisco, CA
Click here to add this to my saved trials